Status:
COMPLETED
Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Lead Sponsor:
New York University
Collaborating Sponsors:
New York State Psychiatric Institute
Conditions:
Psychosis
Eligibility:
All Genders
16-30 years
Phase:
PHASE1
Brief Summary
While great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made in the identification...
Detailed Description
This project seeks to understand how individuals already in a high-risk state will interpret genetic information informing risk of 'conversion' to a full disorder. How individuals interpret this possi...
Eligibility Criteria
Inclusion
- Male or females between the ages of 16- 30
- Current or previous COPE participant
- Identified as at clinical high risk for psychosis as defined as having at least one of the following: a)attenuated positive symptoms b)brief intermittent positive symptoms
Exclusion
- Meeting CHR via only the Genetic risk and deterioration (GRD) syndrome. If the participant meets the GRD syndrome only, the investigators exclude the rare Genetic risk + deterioration (GRD) syndrome (comprising \<1% of CHR cases) because GRD requires having a 1st degree relative with any psychotic disorder, which may be linked with stronger reactions to genetic framings.
- IQ \< 80
- Inability to adopt hypothetical situation
Key Trial Info
Start Date :
November 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04325568
Start Date
November 16 2020
End Date
July 31 2022
Last Update
March 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032